Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1

Virology

Volumn 351, Issue 2, 2006, Pages 404-419

  Diaz Griffero, Felipe ^a   Vandegraaff, Nick ^a   Li, Yuan ^a   McGee Estrada, Kathleen ^a   Stremlau, Matthew ^a   Welikala, Sohanya ^a   Si, Zhihai ^a   Engelman, Alan ^a   Sodroski, Joseph ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Capsid; Cyclophilin; HIV; Restriction factors; Retrovirus; Reverse transcription; Tropism; Uncoating

Indexed keywords

PROTEIN; PROTEIN TRIMCYP; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE FUSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONKEY; NONHUMAN; PRIORITY JOURNAL; RETROPOSON; RETROVIRUS; VIRUS CAPSID;

ANIMALS; AOTIDAE; CAPSID; CARRIER PROTEINS; CELL LINE; CYCLOPHILIN A; GENE EXPRESSION REGULATION; HIV-1; HUMANS; MUTATION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; VIRUS REPLICATION;

AOTUS TRIVIRGATUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 33746480156     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.03.023     Document Type: Article

References (54)

1. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71 (1997) 5871-5877
2. Besnier C., Takeuchi Y., and Towers G. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11920-11925
3. Bosco D.A., and Kern D. Catalysis and binding of cyclophilin A with different HIV-1 capsid constructs. Biochemistry 43 (2004) 6110-6119
4. Bosco D.A., Eisenmesser E.Z., Pochapsky S., Sundquist W.I., and Kern D. Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 5247-5252
5. Butler S.L., Hansen M.S., and Bushman F.D. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7 (2001) 631-634
6. Chatterji U., Bobardt M.D., Stanfield R., Ptak R.G., Pallansch L.A., Ward P.A., Jones M.J., Stoddard C.A., Scalfaro P., Dumont J.M., Besseghir K., Rosenwirth B., and Gallay P.A. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J. Biol. Chem. 280 (2005) 40293-40300
7. Cowan S., Hatziioannou T., Cunningham T., Muesing M.A., Gottlinger H.G., and Bieniasz P.D. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11914-11919
8. Diaz-Griffero F., Hoschander S.A., and Brojatsch J. Endocytosis is a critical step in entry of subgroup B avian leukosis viruses. J. Virol. 76 (2002) 12866-12876
9. Dodding M.P., Bock M., Yap M.W., and Stoye J.P. Capsid processing requirements for abrogation of Fv1 and Ref1 restriction. J. Virol. 79 (2005) 10571-10577
10. Forshey B.M., Shi J., and Aiken C. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J. Virol. 79 (2005) 869-875
11. Gamble T.R., Vajdos F.F., Yoo S., Worthylake D.K., Houseweart M., Sundquist W.I., and Hill C.P. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87 (1996) 1285-1294
12. Ganser-Pornillos B.K., von Schwedler U.K., Stray K.M., Aiken C., and Sundquist W.I. Assembly properties of the human immunodeficiency virus type 1 CA protein. J. Virol. 78 (2004) 2545-2552
13. Ganser B.K., Li S., Klishko V.Y., Finch J.T., and Sundquist W.I. Assembly and analysis of conical models for the HIV-1 core. Science 283 (1999) 80-83
14. Gatanaga H., Das D., Suzuki Y., Yeh D.D., Hussain K.A., Ghosh A.K., and Mitsuya H. Altered HIV-1 gag interactions with cyclophilin A (Cyp A) upon acquisition of H219G and H219P substitutions in the Cyp A binding loop. J. Biol. Chem. (2006) (electonic publication ahead of print)
15. Hatziioannou T., Cowan S., Goff S.P., Bieniasz P.D., and Towers G.J. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22 (2003) 385-394
16. Hatziioannou T., Perez-Caballero D., Yang A., Cowan S., and Bieniasz P.D. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10774-10779
17. Hatziioannou T., Cowan S., Von Schwedler U.K., Sundquist W.I., and Bieniasz P.D. Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J. Virol. 78 (2004) 6005-6012
18. Hatziioannou T., Perez-Caballero D., Cowan S., and Bieniasz P.D. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J. Virol. 79 (2005) 176-183
19. Hofmann W., Schubert D., LaBonte J., Munson L., Gibson S., Scammell J., Ferrigno P., and Sodroski J. Species-specific, postentry barriers to primate immunodeficiency virus infection. J. Virol. 73 (1999) 10020-10028
20. Javanbakht H., Diaz-Griffero F., Stremlau M., Si Z., and Sodroski J. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5α. J. Biol. Chem. 280 (2005) 26933-26940
21. Jin Z., Jin L., Peterson D.L., and Lawson C.L. Model for lentivirus capsid core assembly based on crystal dimers of EIAV p26. J. Mol. Biol. 286 (1999) 83-93
22. Julias J.G., Ferris A.L., Boyer P.L., and Hughes S.H. Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J. Virol. 75 (2001) 537-546
23. Keckesova Z., Ylinen L.M., and Towers G.J. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10780-10785
24. Kootstra N.A., Munk C., Tonnu N., Landau N.R., and Verma I.M. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 1298-1303
25. Li S., Hill C.P., Sundquist W.I., and Finch J.T. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407 (2000) 409-413
26. Lu R., Limon A., Devroe E., Silver P.A., Cherepanov P., and Engelman A. Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication. J. Virol. 78 (2004) 12735-12746
27. Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., and Goff S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73 (1993) 1067-1078
28. Matlin K.S., Reggio H., Helenius A., and Simons K. Pathway of vesicular stomatitis virus entry leading to infection. J. Mol. Biol. 156 (1982) 609-631
29. Mische C.C., Javanbakht H., Song B., Diaz-Griffero F., Stremlau M., Strack B., Si Z., and Sodroski J. Retroviral restriction factor TRIM5alpha is a trimer. J. Virol. 79 (2005) 14446-14450
30. Munk C., Brandt S.M., Lucero G., and Landau N.R. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13843-13848
31. mac infection. J. Virol. 79 (2005) 8870-8877
32. Nisole S., Lynch C., Stoye J.P., and Yap M.W. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 13324-13328
33. Nisole S., Stoye J.P., and Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat. Rev., Microbiol. 3 (2005) 799-808
34. Olsen J.C. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther. 5 (1998) 1481-1487
35. Owens C.M., Yang P.C., Gottlinger H., and Sodroski J. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J. Virol. 77 (2003) 726-731
36. Owens C.M., Song B., Perron M.J., Yang P.C., Stremlau M., and Sodroski J. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J. Virol. 78 (2004) 5423-5437
37. Perez-Caballero D., Hatziioannou T., Zhang F., Cowan S., and Bieniasz P.D. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J. Virol. 79 (2005) 15567-15572
38. Perron M.J., Stremlau M., Song B., Ulm W., Mulligan R.C., and Sodroski J. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11827-11832
39. Ribeiro I.P., Menezes A.N., Moreira M.A., Bonvicino C.R., Seuanez H.N., and Soares M.A. Evolution of cyclophilin A and TRIMCyp retrotransposition in New World primates. J. Virol. 79 (2005) 14998-15003
40. Sawyer S.L., Wu L.I., Emerman M., and Malik H.S. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2832-2837
41. Sayah D.M., and Luban J. Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. J. Virol. 78 (2004) 12066-12070
42. Sayah D.M., Sokolskaja E., Berthoux L., and Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430 (2004) 569-573
43. Sebastian S., and Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2 (2005) 40
44. Seglen P.O. Inhibitors of lysosomal function. Methods Enzymol. 96 (1983) 737-764
45. Song B., Javanbakht H., Perron M., Park D.H., Stremlau M., and Sodroski J. Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J. Virol. 79 (2005) 3930-3937
46. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., and Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 (2004) 848-853
47. Stremlau M., Perron M., Welikala S., and Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J. Virol. 79 (2005) 3139-3145
48. Stremlau, M., Perron, M., Lee, M., Yuan, L., Song, B., Javanbakht, H., Diaz-Griffero, F., Anderson, D.J., Sundquist, W.I., Sodroski, J., in press. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5 (restriction factor. Proc. Natl. Acad. Sci. U.S.A.
49. Towers G.J., Hatziioannou T., Cowan S., Goff S.P., Luban J., and Bieniasz P.D. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9 (2003) 1138-1143
50. Vajdos F.F., Yoo S., Houseweart M., Sundquist W.I., and Hill C.P. Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein. Protein Sci. 6 (1997) 2297-2307
51. Vandegraaff N., Kumar R., Burrell C.J., and Li P. Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA. J. Virol. 75 (2001) 11253-11260
52. Yap M.W., Nisole S., Lynch C., and Stoye J.P. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10786-10791
53. Yap M.W., Nisole S., and Stoye J.P. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 15 (2005) 73-78
54. Yoo S., Myszka D.G., Yeh C., McMurray M., Hill C.P., and Sundquist W.I. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J. Mol. Biol. 269 (1997) 780-795